ArticleNeuro-oncology2016
Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients.
Open access · bronzeAbstract read
In one paragraph
Article in Neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 37 citations in OpenAlex.
- Imaging strategies for delineating glioma margins: Aiming at precise therapy.Fundamental research · 2026Review
- Fully automated Res3DNet model to predict IDH mutation of gliomas from whole-brain MRI free of tumor segmentation.iScience · 2026Article
- Glioblastoma metabolomics: uncovering biomarkers for diagnosis, prognosis and targeted therapy.Journal of experimental & clinical cancer research : CR · 2025Review
- Treatment of Isocitrate Dehydrogenase-Mutant Gliomas.Advances in oncology · 2025Article
- Radiosynthesis and biological evaluation of [European journal of nuclear medicine and molecular imaging · 2024Article
- The role and potential of using quantitative MRI biomarkers for imaging guidance in brain cancer radiotherapy treatment planning: A systematic review.Physics and imaging in radiation oncology · 2023Review
- In Vivo 2-Hydroxyglutarate Monitoring With Edited MR Spectroscopy for the Follow-up ofNeurology · 2023Article
- A Comparative Study Between Tumor Blood Vessels and Dynamic Contrast-enhanced MRI for Identifying Isocitrate Dehydrogenase Gene 1 (IDH1) Mutation Status in Glioma.Current medical science · 2022Article
- Improving D-2-hydroxyglutarate MR spectroscopic imaging in mutant isocitrate dehydrogenase glioma patients with multiplexed RF-receive/BNMR in biomedicine · 2022Article
- Motion correction methods for MRS: experts' consensus recommendations.NMR in biomedicine · 2021Article
- Advanced magnetic resonance spectroscopic neuroimaging: Experts' consensus recommendations.NMR in biomedicine · 2021Article
- Accelerated MR spectroscopic imaging-a review of current and emerging techniques.NMR in biomedicine · 2021Review
- Review
- An integrated RF-receive/BScientific reports · 2020Article
- Article
- In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020Article
- Magnetic resonance spectroscopic imaging in gliomas: clinical diagnosis and radiotherapy planning.BJR open · 2020Review
- 3D high-resolution imaging of 2-hydroxyglutarate in glioma patients using DRAG-EPSI at 3T in vivo.Magnetic resonance in medicine · 2019Article
- Article
- The Role of Advanced Brain Tumor Imaging in the Care of Patients with Central Nervous System Malignancies.Current treatment options in oncology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 3 countries.
Kourosh Jafari-KhouzaniMartinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (K.J.-K., W.B., B.R.R., O.C.A.); Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (F.L., D.P.C.); Department of Neurosurgery, Charité Medical University, Berlin, Germany (F.L.); High Field MR Center, Department of Biomedical Imaging and Image-Guided Therapy, Medical University Vienna, Vienna, Austria (W.B.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (O.R., G.R.G.); Pappas Center of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (E.G., A.S.C., T.T.B.); Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (J.U., H.A.S.).
Franziska LoebelMartinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (K.J.-K., W.B., B.R.R., O.C.A.); Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (F.L., D.P.C.); Department of Neurosurgery, Charité Medical University, Berlin, Germany (F.L.); High Field MR Center, Department of Biomedical Imaging and Image-Guided Therapy, Medical University Vienna, Vienna, Austria (W.B.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (O.R., G.R.G.); Pappas Center of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (E.G., A.S.C., T.T.B.); Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (J.U., H.A.S.).
Wolfgang BognerMartinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (K.J.-K., W.B., B.R.R., O.C.A.); Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (F.L., D.P.C.); Department of Neurosurgery, Charité Medical University, Berlin, Germany (F.L.); High Field MR Center, Department of Biomedical Imaging and Image-Guided Therapy, Medical University Vienna, Vienna, Austria (W.B.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (O.R., G.R.G.); Pappas Center of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (E.G., A.S.C., T.T.B.); Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (J.U., H.A.S.).
Otto RapalinoMartinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (K.J.-K., W.B., B.R.R., O.C.A.); Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (F.L., D.P.C.); Department of Neurosurgery, Charité Medical University, Berlin, Germany (F.L.); High Field MR Center, Department of Biomedical Imaging and Image-Guided Therapy, Medical University Vienna, Vienna, Austria (W.B.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (O.R., G.R.G.); Pappas Center of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (E.G., A.S.C., T.T.B.); Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (J.U., H.A.S.).
Gilberto R GonzalezMartinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (K.J.-K., W.B., B.R.R., O.C.A.); Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (F.L., D.P.C.); Department of Neurosurgery, Charité Medical University, Berlin, Germany (F.L.); High Field MR Center, Department of Biomedical Imaging and Image-Guided Therapy, Medical University Vienna, Vienna, Austria (W.B.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (O.R., G.R.G.); Pappas Center of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (E.G., A.S.C., T.T.B.); Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (J.U., H.A.S.).
Elizabeth GerstnerMartinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (K.J.-K., W.B., B.R.R., O.C.A.); Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (F.L., D.P.C.); Department of Neurosurgery, Charité Medical University, Berlin, Germany (F.L.); High Field MR Center, Department of Biomedical Imaging and Image-Guided Therapy, Medical University Vienna, Vienna, Austria (W.B.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (O.R., G.R.G.); Pappas Center of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (E.G., A.S.C., T.T.B.); Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (J.U., H.A.S.).
Andrew S ChiMartinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (K.J.-K., W.B., B.R.R., O.C.A.); Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (F.L., D.P.C.); Department of Neurosurgery, Charité Medical University, Berlin, Germany (F.L.); High Field MR Center, Department of Biomedical Imaging and Image-Guided Therapy, Medical University Vienna, Vienna, Austria (W.B.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (O.R., G.R.G.); Pappas Center of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (E.G., A.S.C., T.T.B.); Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (J.U., H.A.S.).
Tracy T BatchelorMartinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (K.J.-K., W.B., B.R.R., O.C.A.); Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (F.L., D.P.C.); Department of Neurosurgery, Charité Medical University, Berlin, Germany (F.L.); High Field MR Center, Department of Biomedical Imaging and Image-Guided Therapy, Medical University Vienna, Vienna, Austria (W.B.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (O.R., G.R.G.); Pappas Center of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (E.G., A.S.C., T.T.B.); Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (J.U., H.A.S.).
Bruce R RosenMartinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (K.J.-K., W.B., B.R.R., O.C.A.); Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (F.L., D.P.C.); Department of Neurosurgery, Charité Medical University, Berlin, Germany (F.L.); High Field MR Center, Department of Biomedical Imaging and Image-Guided Therapy, Medical University Vienna, Vienna, Austria (W.B.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (O.R., G.R.G.); Pappas Center of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (E.G., A.S.C., T.T.B.); Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (J.U., H.A.S.).
Jan UnkelbachMartinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (K.J.-K., W.B., B.R.R., O.C.A.); Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (F.L., D.P.C.); Department of Neurosurgery, Charité Medical University, Berlin, Germany (F.L.); High Field MR Center, Department of Biomedical Imaging and Image-Guided Therapy, Medical University Vienna, Vienna, Austria (W.B.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (O.R., G.R.G.); Pappas Center of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (E.G., A.S.C., T.T.B.); Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (J.U., H.A.S.).
Helen A ShihMartinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (K.J.-K., W.B., B.R.R., O.C.A.); Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (F.L., D.P.C.); Department of Neurosurgery, Charité Medical University, Berlin, Germany (F.L.); High Field MR Center, Department of Biomedical Imaging and Image-Guided Therapy, Medical University Vienna, Vienna, Austria (W.B.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (O.R., G.R.G.); Pappas Center of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (E.G., A.S.C., T.T.B.); Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (J.U., H.A.S.).
Daniel P CahillMartinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (K.J.-K., W.B., B.R.R., O.C.A.); Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (F.L., D.P.C.); Department of Neurosurgery, Charité Medical University, Berlin, Germany (F.L.); High Field MR Center, Department of Biomedical Imaging and Image-Guided Therapy, Medical University Vienna, Vienna, Austria (W.B.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (O.R., G.R.G.); Pappas Center of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (E.G., A.S.C., T.T.B.); Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (J.U., H.A.S.).
Ovidiu C AndronesiMartinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (K.J.-K., W.B., B.R.R., O.C.A.); Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (F.L., D.P.C.); Department of Neurosurgery, Charité Medical University, Berlin, Germany (F.L.); High Field MR Center, Department of Biomedical Imaging and Image-Guided Therapy, Medical University Vienna, Vienna, Austria (W.B.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (O.R., G.R.G.); Pappas Center of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (E.G., A.S.C., T.T.B.); Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (J.U., H.A.S.).
Charité - Universitätsmedizin Berlin · DECenter for Neuro-Oncology · USAthinoula A. Martinos Center for Biomedical Imaging · USMassachusetts General Hospital · USHarvard University · US
Funding
Targeting the Vasular SystemP50CA165962 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Tracy T Batchelor · 2013 to 2026
$33.5MQuantify treatment response in IDH1 mutant glioma patients with metabolic MRIK22CA178269 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI ANDRONESI, OVIDIU C · 2013 to 2016
$601kNCI NIH HHS K22 CA178269NCI NIH HHS P50 CA165962
Abstract
backgroundGliomas with mutant isocitrate dehydrogenase (IDH) produce high levels of 2-hydroxyglutarate (2HG) that can be quantitatively measured by 3D magnetic resonance spectroscopic imaging (MRSI). Current glioma MRI primarily relies upon fluid-attenuated inversion recovery (FLAIR) hyperintensity for treatment planning, although this lacks specificity for tumor cells. Here, we investigated the relationship between 2HG and FLAIR in mutant IDH glioma patients to determine whether 2HG mapping is valuable for radiotherapy planning.
methodsSeventeen patients with mutant IDH1 gliomas were imaged by 3 T MRI. A 3D MRSI sequence was employed to specifically image 2HG. FLAIR imaging was performed using standard clinical protocol. Regions of interest (ROIs) were determined for FLAIR and optimally thresholded 2HG hyperintensities. The overlap, displacement, and volumes of 2HG and FLAIR ROIs were calculated.
resultsIn 8 of 17 (47%) patients, the 2HG volume was larger than FLAIR volume. Across the entire cohort, the mean volume of 2HG was 35.3 cc (range, 5.3-92.7 cc), while the mean volume of FLAIR was 35.8 cc (range, 6.3-140.8 cc). FLAIR and 2HG ROIs had mean overlap of 0.28 (Dice coefficients range, 0.03-0.57) and mean displacement of 12.2 mm (range, 3.2-23.5 mm) between their centers of mass.
conclusionsOur results indicate that for a substantial number of patients, the 2HG volumetric assessment of tumor burden is more extensive than FLAIR volume. In addition, there is only partial overlap and asymmetric displacement between the centers of FLAIR and 2HG ROIs. These results may have important implications for radiotherapy planning of IDH mutant glioma.
Indexed as
AdultAged, 80 and overBrainBrain NeoplasmsFemaleGliomaGlutaratesHumansIsocitrate DehydrogenaseMagnetic Resonance ImagingMagnetic Resonance SpectroscopyMaleMiddle AgedMutationRadiotherapy Planning, Computer-AssistedYoung Adultalpha-hydroxyglutarateGlutaratesIDH1 protein, humanIsocitrate Dehydrogenase2-hydroxyglutarate (2HG)gliomaisocitrate dehydrogenase (IDH) mutationmagnetic resonance spectroscopic imaging (MRSI)radiotherapy
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.